6 results about "Platelet-activating factor" patented technology

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation process of azelastine hydrochloride, which comprises four steps of condensation reduction, hydrochloric acid hydrolysis, cyclization and hydrochloric acid salification. According to the method, the reaction efficiency, the product yield and the purity are improved, the production cost and the operation difficulty are reduced, and a stable, cost-controllable and repeatable preparation process is formed. The prepared azelastine hydrochloride is a long-acting anti-allergic drug, has dual effects of resisting histamine and inflammation, has high affinity to a receptor, effectively blocks histamine release of mast cells and basic granulocytes, has wide pharmacological effects on leukotriene, kinin, platelet activating factors and other inflammatory chemical mediators, and can be used for preparing an anti-allergic drug. Therefore, azelastine can effectively relieve typical symptoms of allergic conjunctivitis, such as pruritus, conjunctival congestion, lacrimation, conjunctival edema and the like.

This invention discloses the application of PAFAH2 protein in the preparation of products for the prevention and / or treatment of ischemia-reperfusion injury. This invention reveals for the first time that platelet-activating factor and its phospholipid-like components can induce ferroptosis in cells. On the one hand, they can directly increase cell membrane permeability; on the other hand, they can be secreted extracellularly, acting as propagation factors for ferroptosis and promoting its spread within the cell population. PAFAH2, as an intracellular specific hydrolase against platelet-activating factor and its phospholipid-like components, resists ferroptosis by scavenging these oxidative substrates. Ischemia-reperfusion leads to ferroptosis in tissue cells. This invention, through the injection of human recombinant PAFAH2 protein, removes oxidatively truncated phospholipids generated during reperfusion, thereby protecting tissue cells from the occurrence and spread of ferroptosis caused by lipid peroxidation and inhibiting large-area tissue damage caused by ischemia-reperfusion.

The invention discloses application of a platelet activating factor in preparation of a medicine for treating endometrial cancer. Cell experiments and animal in-vivo experiments prove that the platelet activating factor can effectively inhibit proliferation of the endometrial cancer and inhibit in-vivo growth of the endometrial cancer, the targeted binding effect of PAF and ATF3 is clarified, a new method is provided for treatment of the endometrial cancer, and the platelet activating factor is expected to be applied to preparation of drugs for inhibiting proliferation of the endometrial cancer and has a wide application prospect. The invention has important significance for clinical treatment of endometrial cancer.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.